Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Q2 FY23 Earnings Presentation
30 slides from Orchid Pharma's earnings presentation, Nov 18, 2022
Slide 1: Results Q2-FY23
September 2022 Results Q2-FY23
Slide 2: Safe Harbor
SAFE HARBOR September 2022 This presentation and the accompanying slides (the “Presentation”), which have been prepared by Orchid Pharma Ltd (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for
Slide 3: Current Results
September 2022 Current Results 18 November 2022
Slide 4: Q2FY23 Performance Highlights
Q2FY23 Performance Highlights Q2FY23 Key Financial Overview (Y-o-Y) Revenue Gross Profit EBITDA EBITDA% 36% 29% 165.2Crs 64.8 Crs 23.7Crs 157% 4
Slide 5: Progress So far
September 2022 Progress So far 18 November 2022
Slide 6: Progress of Turnaround
September 2022 Before takeover Progress of Turnaround After takeover Revenues EBITDA 600.0 560.0 53.0 50.0 508.0 450.0 39.0 17.0 296.0 217.0 FY19 FY20 FY21 FY22 H122 H123 -18.0 -25.0 FY19 FY20 FY21 FY22 H122 H123 18 November 2022 © Copyright OrchidPharma Ltd. All Rights Reserved 6
Slide 7: Company overview
September 2022 1 2 Company PIONEER IN CEPHALOSPORIN ANTIBIOTICS R&D Focused, Inventor of ABOUT DHANUKA GROUP ~ 2500 Crore diversified group. Interests in Crop Care and Pharma overview Enmetazobactam (Ph.-3 Trials done in US Dhanuka Laboratories is the Pharma arm. & EU) >20 years in Antibiotics space
Slide 8: Background and Pedigree
September 2022 Background Dhanuka Laboratories Ltd. and Pedigree Pharmaceutical arm started in 1998 Leader in Cephalosporin Antibiotics Dhanuka Agritech Ltd. in Emerging markets JV with Otsuka - Japan, for Flagship of the Group founded in 1980. manufacturing advanced intermediates Listed o
Slide 9: Why Orchid
September 2022 Why Orchid 18 November 2022
Slide 10: Strong R&D capabilities
September 2022 Strong R&D capabilities Orchid’s expertise All these combined, give us the Orchid pharma encompass the entire strength and ability to file First to File spectrum of Para 4 applications for US and other has been Pharmaceutical R&D regulatory markets. focused on R&D, 1. Synthesis R&D No
Slide 11: Widest range of Cephalosporins
September 2022 Widest range of Ready to launch Cephalosporins Under development Generation Generation Generation Generation Generation Generation 1 2 3 4 5 6 Oral Cefadroxil Cefprozil Cefdinir Cefalexin Cefuroxime Cefditoren Cefradine Cefixime Cefpodoxime Ceftibuten Sterile Cef
Slide 12: Leading Integrated Cephalosporin API company
September 2022 Leading - Integrated Cephalosporin API company Vertically integrated with credentials in research, development, manufacturing and marketing Integrated facilities from Intermediates to API spread across 60 acre, approved worldwide Presence across the antibiotic domains spread acr
Slide 13: Experienced Board & Management Team
September 2022 Mr. Ram Gopal Mr. Manish Dhanuka Mr. Arun Dhanuka Mr. Mridul Dhanuka Experienced Agarwal Chairman and Non- Managing Director Visionary Leader at the Non-Executive Director Whole-Time Director Chemical Engineer & Board & Executive Director Founder Chairman of helm of affairs of Pharma
Slide 14: Future Strategy
September 2022 Future Strategy 18 November 2022
Slide 15: Growth Drivers
September 2022 Growth Drivers 01 Scale 02 7 ACA and Downstream Products 03 New Products New Chemical Entity – 04 Enmetazobactam 18 November 2022 © Copyright OrchidPharma Ltd. All Rights Reserved 15
Slide 16: Scale – Capacity Addition
September 2022 Scale – 1200 Capacity 1000 Addition 800 600 400 200 0 Sterile Oral Total As Acquired Improved After Expansion 18 November 2022 © Copyright OrchidPharma Ltd. All Rights Reserved 16
Slide 17: 7ACA and Downstream Products
September 2022 7ACA and Downstream Products Growth Driver 18 November 2022 17
Slide 18: Size of 7ACA Market
September 2022 Size of 7ACA Market (including downstream products) World Market India Market Orchid ~ 10000MT ~ $600mn India Market Size ~ 4000MT of 7ACA 1000MTPA per annum growing at 5% CAGR Key Downstream Products – Adding 500MT demand per Sterile year. Ceftriaxone – 6000MTPA China c
Slide 19: PLI – A Step towards Self-Reliance
September 2022 PLI – A Step towards Orchid has received 1000MTPA approval from Government of India in its WoS – Orchid BioPharma Ltd. (OBPL) ~ Price of 7ACA = $63 • PLI from GOI @ 20% Location – Jammu Benefits under New Central Sector Scheme for Industrial Development of Union Territory of Jam
Slide 20: 7ACA Downstream Products
September 2022 7ACA Downstream Products 80% will be used by Orchid-in-house 20% will be sold in the open market 55% shall be used to make 1000MT of downstream products at an average price of $85 25% is Orchid’s current self Imports 18 November 2022 © Copyright OrchidPharma Ltd. All Rights Reserv
Slide 21: New Products
September 2022 New PRODUCTS Growth Driver 18 November 2022 21
Slide 22: Ceftaroline
September 2022 Ceftaroline ORIGINATOR • Forest Labs (Allergan) MARKET SIZE • US - USD160mn • ~ INR 1250 Crore After Patent Expiry in 2023, volume will multiply and price will reduce We estimate a net market size multiplication by 2x after Genericization ~ 2500 Cr Orchid Target Dates US Marke
Slide 23: Ceftazidime/ Avibactam
September 2022 Ceftazidime/ Avibactam ORIGINATOR • Allergan / Pfizer MARKET SIZE • USD 450 Mn • ~ INR 3600 Crore PATENT STATUS • US – November 2026 • Emerging Markets – January 2023 After Patent Expiry, volume will multiply, and price will reduce We estimate a net market size multiplicatio
Slide 24: Future Products Pipeline
September 2022 Future Products Pipeline Ceftolozane - Tazobactam Cefiderocol Originator – Merck Originator Shionogi First Approved in US Jan 2016 First Approved in US Nov 2019 18 November 2022 © Copyright OrchidPharma Ltd. All Rights Reserved 24
Slide 25: NCE Enmetazobactam
September 2022 NCE Enmetazobactam Growth Driver 18 November 2022 25
Slide 26: Antibiotic Resistance – The challenge
September 2022 Antibiotic Resistance – The challenge Poor infection Over- Unnecessary Patients not control in hospitals prescribing of antibiotics used in taking antibiotics and clinics antibiotics Animal Husbandry as prescribed 18 November 2022 © Copyright OrchidPharma Ltd. All Rights Reserved 26
Slide 27: Importance of Enmetazobactam
September 2022 Importance of Enmetazobactam Enmetazobactam – a Beta Lactamase Inhibitor (BLI), lowers the resistance of the Antibiotic to make it effective again Best example – Augmentin of GSK, a 50-year- old drug. Combined with BLI, is largest selling Antibiotic in the world today Phase 3 Cl
Slide 28: World Market Estimation Indicators
September 2022 World Market Estimation Indicators PIP-TAZ market ~ $1bn at Patent Expiry Looking at its Potential, Estimated annual global sales of AVYCAZ market of USD 200 Mn –300 Mn pa (10Y Avg) December 2020, out-licensed to Shanghai Haini ~$450mn Pharmaceuticals for Greater China at a value
Slide 29: Enmetazobactam - Domestic
September 2022 Enmetazobactam - Domestic Domestic Injectable Antibiotic Size 7000 Crore Largest Products PIP-TAZ 800 ~ 1000 Cr MEROPENEM 20% Better Efficacy ~ 1000 Cr This is a Carbapenem. CEFTRIAXONE Last Resort Antibiotic. Orchid Target Dates 1200 ~ 1500 Cr Should be saved for more Filing of App
Slide 30: Thank You!
OrchidPharma? ——— |S